Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesHousaiyin Li, Robert L. Ferris, Matthias Brand et al.|Cancer Cell|2025Cited by 64
Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck CancerDan P. Zandberg, Julie E. Bauman, Lazar Vujanović et al.|Journal of Clinical Oncology|2025Cited by 20
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker CorrelativesRobert L. Ferris, Julie E. Bauman, P. Torres-Saavedra et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0
Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)Julie E. Bauman, Robert L. Ferris, J. Harris et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0
493 Distinct correlative signatures of CD4<sup>+</sup> helper and regulatory T cells associate with response to different neoadjuvant immune checkpoint inhibitor combinations in HNSCCMatthias Brand, Robert L. Ferris, Aditi Kulkarni et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0